Safety and Efficacy of SBRT in the Reirradiation for Ultra-central Thoracic Malignant Tumors

Launched by PEKING UNIVERSITY THIRD HOSPITAL · Dec 26, 2021

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called Stereotactic Body Radiation Therapy (SBRT) for patients with recurrent thoracic tumors that are hard to treat. These tumors, known as "ultra-central" tumors, are located very close to important structures in the chest, making standard treatments risky. The goal of this study is to see if SBRT can safely and effectively treat these tumors in patients who have already received radiation therapy in the past.

To participate in this trial, patients must have a diagnosed malignant tumor located in the ultra-central area of the chest, with a size of 5 cm or smaller. They should not have extensive cancer spread to other parts of the body, and their overall health needs to be stable enough to tolerate radiation treatment. Participants can expect to receive focused radiation therapy aimed at their tumors while minimizing damage to surrounding healthy tissues. This trial is currently recruiting and aims to gather more information on how well SBRT works in this challenging situation, as well as any side effects that may occur.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Pathological diagnosis is malignant tumor.
• • The location of the target lesion belongs to the ultra-central type of chest.
• • The target lesion had a history of radiotherapy, and the lesion diameter is ≤ 5cm.
• • There is no extensive systemic metastasis or although there is metastasis, the metastasis have been controlled by previous treatment.
• • KPS\>70, no serious or uncontrolled underlying diseases, such as severe or uncontrolled hypertension, diabetes, cardiovascular and cerebrovascular diseases and organ dysfunction, and patients are expected to be tolerated by radiotherapy.
• Exclusion Criteria:
• • Poor basic pulmonary function or symptom correlation caused by various reasons, unable to lie flat or cooperate with treatment.
• • The general condition is poor, and the expected survival time is less than 3 months.
• • Psychiatric patients or poor compliance, unable to cooperate to complete treatment.
• • For other reasons, the researcher believes that it is not suitable to participate in this trial.